Expertise

Our Investigators

Internationally recognized leaders in the field, PCCTC investigators come from the nation’s top academic medical centers where they are actively engaged in innovative, multidisciplinary prostate cancer research. Leveraging their unique insights into the underlying biology of the disease, our investigators developed the universally adopted clinical states model of prostate cancer and initiated one of the first efforts in oncology to prospectively validate endpoints proposed in definitive phase III trials, PCWG2. The individual research objectives of our investigators are well represented in our clinical trial portfolio and unified by our translational, team-based approach to drug and biomarker development.

Drug Development

The PCCTC selects and prioritizes clinical development opportunities based on our investigators’ unparalleled understanding of the global clinical trials landscape, the strength of the underlying science, and the potential to address critical unmet needs across prostate cancer’s clinical spectrum. Our studies are characterized by close interaction between basic scientists and clinical investigators to optimize the flow of promising agents into early-phase studies, and the complimentary development of novel trial designs, endpoints and predictive biomarkers which ensure the decision to advance or to discontinue a program is made objectively and rapidly. The PCCTC’s Management Team and Scientific Oversight Committee work together to address the scientific, legal, regulatory, database, budgetary, and management concerns of every trial to further accelerate the development of successful drug candidates.

Biomarker Development

A cornerstone of the PCCTC’s research strategy is the co-development of therapies and biomarkers. To transform the clinical management of prostate cancer in the near term, it is essential to develop drugs in more precisely defined and biologically relevant patient groups. The ability to screen for patients most likely to respond to a novel agent is essential for both shortening development timelines and reducing exposure to unnecessary toxicity from ineffective treatment. Following the FDA’s Critical Path Initiative, we initiated one of the first endeavors in oncology to define blood and imaging-based biomarkers, develop analytically valid assays for them, and subsequently design and conduct the dedicated clinical trials necessary to establish their clinical validity. Capitalizing on the intellectual synergy of our investigators, our extensive clinical trial portfolio, and our many resources and basic science collaborations, our long-term objective is to establish intermediate or surrogate endpoints which can predict clinical benefit and form the basis for accelerated drug approvals.

Recent News +++

The PCCTC at ASCO22

Press Releases by PCCTC June 3, 2022

More than 40,000 oncology professionals from around the world will convene at the annual A...

Learn More

Lantheus Collaborates with The Prostate Cancer Clinical Trial Consortium (PCCTC) To Advance AI-Enabled Imaging Biomarkers in Prostate Cancer

Press Releases by PCCTC January 27, 2022

NORTH BILLERICA, MA, January 27, 2022 – Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus...

Learn More

Genetic Testing for Prostate Cancer: Considerations for Practice Virtual Genetics Board

Press Releases by PCCTC December 8, 2021

The Prostate Cancer Clinical Trials Consortium (PCCTC) Genetics Germline Working Group is ...

Learn More

The PCCTC Seeks Director, Clinical Data Management & Informatics

Press Releases by PCCTC November 16, 2021

The Prostate Cancer Clinical Trials Consortium (PCCTC) was initiated in 2005 by the Prosta...

Learn More
View More News +

Follow Us

@ThePCCTC recognizes the pivotal role of ethical #prostatecancer research and champions diversity, equity, and incl… https://t.co/lKmQ0oMSHf
RT @ChrisSweens1: @montypal 100% agree with @neerajaiims path and these slides provide rationale and strategy to get us on the path via a g…
Committed to translating scientific discoveries to improved standards of care, @ThePCCTC team members from across t… https://t.co/gic1zpyJys

Join our team of dedicated clinical research professionals! The Prostate Cancer Clinical Trials Consortium is currently seeking a Quality Manager and Clinical Data Manager to help fulfill our…

2018-23944 Clinical Data Manager, Prostate Cancer Clinical Trials Consortium (PCCTC) | Memorial Sloan Kettering Cancer Center Careers

careers.mskcc.org

Committed to world-class science!

Our services translate scientific discoveries into improved standards of care, ensuring efficient trial selection, reporting, site management, clinical operations and data analyses.